Table 2.
Acute toxicity in patients treated by RT-TACE-LEN or TACE-LEN.
| Toxicity | Any Grade | p value | Grade 3-4 | p value | ||
|---|---|---|---|---|---|---|
| Group, No. (%) | Group, No. (%) | |||||
| RT-TACE-LEN (n= 51) |
TACE-LEN (n= 51) |
RT-TACE-LEN (n= 51) |
TACE-LEN (n= 51) |
|||
| Ascites | 7 (13.7) | 6 (11.8) | 0.767 | 3 (5.9) | 2 (3.9) | 0.645 |
| Elevated ALT | 12 (23.5) | 10 (19.6) | 0.630 | 8 (15.7) | 8 (15.7) | >.999 |
| Elevated AST | 13 (25.5) | 11 (21.6) | 0.641 | 10 (19.6) | 9 (17.6) | 0.799 |
| Hyperbilirubinemia | 10 (19.6) | 9 (17.6) | 0.799 | 6 (11.8) | 5 (9.8) | 0.750 |
| Hypoalbuminemia | 9 (17.6) | 7 (13.7) | 0.586 | 1 (2.0) | 1 (2.0) | >0.999 |
| Total | 51 (100.0) | 33 (64.7) | < 0.001 | 28 (54.9) | 25 (49.0) | 0.552 |
ALT, alanine aminotransferase; AST, aspartate aminotransferase; RT, radiation; TACE, trans arterial chemoembolization; LEN, lenvatinib.